^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

Excerpt:
In vivo, PKI-587 inhibited tumor growth in breast (MDA-MB-361, BT474), colon (HCT116), lung (H1975), and glioma (U87MG) xenograft models. PKI-587 at 25 mg/kg (once weekly) shrank large (∼1,000 mm3) MDA-MB-361 tumors and suppressed tumor regrowth. PKI-587 also had significant efficacy in the BT474 [breast; HER2+, PIK3CA (K111N)] xenograft model…
DOI:
10.1158/1078-0432.CCR-10-1694